Bruce Power announced the successful completion of the first Isotope Production System (IPS) installation within a commercial power reactor in the world; a collaborative project with Kinectrics. This milestone marks significant progress toward the production of the Lutetium-177 medical isotopes used in the treatment of neuroendocrine tumors and prostate cancer.
Isogen, the joint venture between Framatome and Kinectrics, developed irradiation capabilities to produce radioactive isotopes in one of Bruce Power’s CANDU-type reactors. The process is based on a system of targets insertion and removal without interrupting the power generation of the reactor.
“Innovation is at the heart what we do. It is the momentum created by Framatome, Kinetrics and Bruce Power that enables us to celebrate this important milestone that contributes to the production of medical isotopes.” said François Gauché, director of Framatome Healthcare. “Through years dedicated to designing, testing and qualifying this innovative transport system, we contribute to improving the value of commercial nuclear reactors beyond providing reliable, low-carbon electricity generation. We look forward to supporting our partners at Kinectrics and Bruce Power as we move forward to provide irradiated targets to our other partner ITM for processing and distribution of Lu177 worldwide.”
